dRx Capital

dRx Capital is a corporate venture capital firm established in 2015 as a joint venture between Novartis and Qualcomm. The firm focuses on investing in early-stage digital health companies that leverage data and digital technology to enhance patient care and outcomes. With a capital commitment of up to $100 million, dRx Capital aims to catalyze the success of digital medicine products, services, and business models by supporting entrepreneurs who are transforming healthcare through innovation. The investment strategy of dRx Capital centers on technology platforms that improve access to healthcare and reimagine the practice of medicine. The firm places a strong emphasis on sectors such as artificial intelligence (AI), machine learning (ML), big data, research and development (R&D) optimization, patient care, and the pharmaceutical supply chain and commercialization. By focusing on these areas, dRx Capital seeks to drive advancements in healthcare delivery and patient outcomes. Over the years, dRx Capital has built a diverse portfolio of companies that align with its investment focus. Notable portfolio companies include Aktana, Animantis, Aspen RxHealth, Cala Health, Cota Health, Flywheel, Freenome, H1, Koneksa, Mekonos, NuvoAir, Omada Health, Pear Therapeutics, Peptone, RxVantage, SchoolCare, Science 37, SomaLogic, Vineti, and Xealth. These investments reflect dRx Capital's commitment to supporting innovative solutions in the healthcare sector. dRx Capital's investment philosophy is rooted in identifying and supporting exceptional entrepreneurs who are leveraging data and digital technology to transform healthcare. By providing capital and strategic guidance, the firm aims to accelerate the development and adoption of digital health solutions that have the potential to make a significant impact on patient care and the broader healthcare ecosystem. In summary, dRx Capital serves as a strategic partner for early-stage digital health companies, offering both financial support and access to the extensive networks of Novartis and Qualcomm. Through its investments, the firm contributes to the advancement of digital medicine and the evolution of healthcare practices worldwide.

Innovative digital health solutions, Strong management teams, Scalable business models, Potential for significant impact on patient care and outcomes